Inhaled Product Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inhaled Product Characterization
The authors discuss the analysis of the resulting data, focusing on methods for the calculation of mass median ærodynamic diameter, one of the metrics routinely used for comparative testing.


Pharmaceutical Technology
pp. s33-s37

References

1. Stimuli to the Revision Process, "Generalized Simplified Approaches for Mass Median Aerodynamic Determination," Pharmacopeial Forum 36 (3) (2010).

2. M. Copley and J. McDonald, Inhalation 3 (11), 14–17 (2009)

3. W.C. Hinds, Aerosol Technology, Properties, Behavior, and Measurement of Airborne Particles (John Wiley & Sons, 2nd ed., 1999).

4. T.K. Church et al., Proc. Respiratory Drug Deliv. XII, 2, 509–509–512 (2010).

5. D.J. Finney, Probit Analysis (Cambridge University Press, Cambridge, 1971).

6. USP 34–NF 29, Physical Tests and Determinations <601> "Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhalers," pp. 237–239.

7. D. Lewis, Inhalation (August 2008).

8. Inhalation Report, "How do you calculate MMAD," (2010), http://www.inhalationreport.com/, accessed 10 Oct. 2011.

9. Tougas et al., AAPS Pharm. Sci. Technol., 10 (4) 1276–1285 (2009)

10. Proceedings of EPAG AIM Workshop at DDL 21 (Edinburgh International Conference Center, Dec. 8–10, 2010).

11. P.N. Pantelides et al., proceedings of RDD Europe (Berlin, 2011), pp. 391–395.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
60%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
20%
Regulatory restrictions
0%
Business decisions to limit production
20%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here